VERAXA Biotech AG has appointed Carl von Halem as its interim Chief Financial Officer, succeeding Torsten Bürgermeister. Von Halem has been instrumental in taking VERAXA public and brings extensive experience in finance and life sciences. The company is finalizing discussions with a permanent CFO to support its growth and will update the market in due course. This leadership change aims to support VERAXA's next phase of expansion in developing novel cancer therapies.
UBS Group AG has notified Bang & Olufsen A/S that its shareholding and voting rights have dropped below the 5% threshold, holding 4.85% as of July 8, 2026. This update is in accordance with the Danish Capital Markets Act, which requires disclosure wh...
Assassin’s Creed Black Flag Resynced, a remake of the 2013 original, sold 2 million copies on its first day, marking a strong launch for Ubisoft. The game achieved the highest concurrent player count ever for the franchise on Steam and topped Twitch ...
VKNG Digital, founded by marketing expert Dave Anderson, has launched to provide high-quality SEO and PPC strategies to small and medium-sized businesses in Lancashire. The agency aims to bridge the gap where smaller businesses often lack access to e...
Strive, a Nasdaq-listed company holding nearly 20,000 Bitcoin on a debt-free balance sheet, is open to selling Bitcoin if it benefits shareholders but aims to remain a net buyer overall. CEO Matt Cole emphasizes outperforming Bitcoin itself rather th...
Apple has filed a lawsuit against OpenAI accusing it of stealing trade secrets and breaching contracts. The complaint alleges that OpenAI’s senior leadership, including Chief Hardware Officer Tang Tan, orchestrated the theft by recruiting Apple emplo...
